Nacreon

Delivery technology / Licensing

The molecule is
only the beginning.

Nacreon develops peptide and peptide-adjacent technologies and licenses them to brands and manufacturers. A Protixa spinoff, we’re starting with Rapid Ions®—a formulation platform focused on peptide delivery and stability.

Our first platform

Rapid Ions®

Peptide-delivery research

Start with what surrounds the peptide.

Rapid Ions® puts the formulation around a peptide to work on delivery and stability. We’re developing alternatives to needle delivery and evaluating applications in nutraceuticals and pharmaceuticals. Explore the research, results and formats behind our first platform.

Inside Rapid Ions® ↗

About Nacreon

From Protixa’s R&D,
Now with a broader purpose.

One technology. Applications across products.

Nacreon grew out of Protixa’s research and development. We bring that work to brands and manufacturers through licensing, starting with Rapid Ions®. Our focus is practical: solve problems in peptide delivery and stability, then develop technologies partners can build into products.

Why Nacreon ↗

For brands and manufacturers

Bring us the product
you’re trying to build.

01 / APPLICATION

Describe the application.

Tell us what you want to make, the format you have in mind and where delivery is proving difficult. Start with the product.

02 / DEVELOPMENT

Identify the work.

We work with you to define the technical questions and the evidence needed to evaluate Rapid Ions® for your product.

03 / LICENSING

Define the license.

Your application sets the scope. Together, we define the rights, responsibilities, and commercial terms for bringing Rapid Ions® into your product.

Newsroom

News from Nacreon.

Company announcements and research updates will appear here as they are ready to share.

Visit the newsroom ↗